IDEAYA Biosciences, Inc.
IDYA
$18.58
-$0.38-2.00%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | 78.48% | -- | -- | -- | -2.49% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 78.48% | -- | -- | -- | -2.49% |
Cost of Revenue | 261.58% | 69.59% | 86.90% | 53.65% | 56.88% |
Gross Profit | -282.18% | -122.70% | -112.74% | -114.25% | -68.42% |
SG&A Expenses | 54.97% | 23.88% | 46.91% | 30.35% | 22.90% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 229.71% | 60.94% | 79.09% | 49.35% | 50.46% |
Operating Income | -243.87% | -99.53% | -98.50% | -94.14% | -58.52% |
Income Before Tax | -283.78% | -88.85% | -88.97% | -67.39% | -40.30% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -283.78% | -88.85% | -88.97% | -67.39% | -40.30% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -283.78% | -88.85% | -88.97% | -67.39% | -40.30% |
EBIT | -243.87% | -99.53% | -98.50% | -94.14% | -58.52% |
EBITDA | -247.72% | -101.65% | -100.39% | -96.18% | -59.51% |
EPS Basic | -186.70% | -31.49% | -36.33% | -7.82% | -3.50% |
Normalized Basic EPS | -152.05% | -31.49% | -36.35% | -7.79% | -34.83% |
EPS Diluted | -186.70% | -31.49% | -36.33% | -7.82% | -3.50% |
Normalized Diluted EPS | -152.05% | -31.49% | -36.35% | -7.79% | -34.83% |
Average Basic Shares Outstanding | 33.86% | 43.65% | 38.60% | 55.28% | 35.56% |
Average Diluted Shares Outstanding | 33.86% | 43.65% | 38.60% | 55.28% | 35.56% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |